ZA200103946B - A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state. - Google Patents

A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state.

Info

Publication number
ZA200103946B
ZA200103946B ZA200103946A ZA200103946A ZA200103946B ZA 200103946 B ZA200103946 B ZA 200103946B ZA 200103946 A ZA200103946 A ZA 200103946A ZA 200103946 A ZA200103946 A ZA 200103946A ZA 200103946 B ZA200103946 B ZA 200103946B
Authority
ZA
South Africa
Prior art keywords
meta
particles
producing particles
amorphous
crystalline
Prior art date
Application number
ZA200103946A
Other languages
English (en)
Inventor
Mikael Bisrat
Saeed Moshashaee
Haakan Nyqvist
Mustafa Demirbueker
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200103946B publication Critical patent/ZA200103946B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Oxygen, Ozone, And Oxides In General (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Recrystallisation Techniques (AREA)
  • Saccharide Compounds (AREA)
ZA200103946A 1998-11-23 2001-05-15 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state. ZA200103946B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9804000A SE9804000D0 (sv) 1998-11-23 1998-11-23 New composition of matter

Publications (1)

Publication Number Publication Date
ZA200103946B true ZA200103946B (en) 2002-10-30

Family

ID=20413377

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200103946A ZA200103946B (en) 1998-11-23 2001-05-15 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state.

Country Status (27)

Country Link
US (1) US6475524B1 (fr)
EP (1) EP1133285B1 (fr)
JP (1) JP4447169B2 (fr)
KR (1) KR100697780B1 (fr)
CN (1) CN1198592C (fr)
AT (1) ATE318583T1 (fr)
AU (1) AU767313B2 (fr)
BR (1) BR9915592A (fr)
CA (1) CA2349633C (fr)
CY (1) CY1105609T1 (fr)
CZ (1) CZ20011778A3 (fr)
DE (1) DE69930158T2 (fr)
DK (1) DK1133285T3 (fr)
EE (1) EE200100275A (fr)
ES (1) ES2258865T3 (fr)
HU (1) HUP0104182A2 (fr)
IL (2) IL143040A0 (fr)
IS (1) IS5946A (fr)
NO (1) NO20012514L (fr)
NZ (1) NZ511494A (fr)
PL (1) PL348523A1 (fr)
PT (1) PT1133285E (fr)
SE (1) SE9804000D0 (fr)
SK (1) SK7032001A3 (fr)
TR (1) TR200101424T2 (fr)
WO (1) WO2000030614A1 (fr)
ZA (1) ZA200103946B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0016002D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
DE10062712A1 (de) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
EP1354581A4 (fr) * 2000-12-26 2007-07-04 Takeda Pharmaceutical Substance poreuse et son procede de fabrication
DE60118983T3 (de) * 2001-07-02 2016-07-07 Micro & Nano Materials Sagl Verfahren zur Herstellung von Nano- und Mikro-Teilchen
GB0126716D0 (en) * 2001-11-07 2002-01-02 Advanced Phytonics Ltd Method for the production of particles
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
RU2006132043A (ru) * 2004-02-06 2008-03-20 МЕДА Фарма ГмбХ унд Ко.КГ (DE) Комбинация и фармацевтический препарат для лечения ринита
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7968575B2 (en) 2004-05-05 2011-06-28 Renopharm Ltd. Nitric oxide donors and uses thereof
EP1753734A1 (fr) 2004-05-05 2007-02-21 Renopharm Ltd. Donneurs d'oxyde nitrique et utilisations de ceux-ci
US8134010B2 (en) 2004-05-05 2012-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof
US7498445B2 (en) 2004-05-05 2009-03-03 Renopharm Ltd. Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
JP2008510015A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
JP5000095B2 (ja) * 2005-03-11 2012-08-15 花王株式会社 有機結晶粒子の製造方法
EP1904219A4 (fr) 2005-07-15 2011-07-27 Map Pharmaceuticals Inc Procede de formation de particules
DE102006030166A1 (de) * 2006-06-29 2008-01-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tempern
WO2009047935A1 (fr) * 2007-10-12 2009-04-16 Ono Pharmaceutical Co., Ltd. Particules fines
AU2008331967B2 (en) * 2007-12-07 2012-10-25 Xspray Microparticles Ab Method and arrangement for the production of particles
JP5138670B2 (ja) * 2009-01-30 2013-02-06 三洋化成工業株式会社 樹脂粒子およびその製造方法
EP3620154A1 (fr) 2009-02-06 2020-03-11 University Of Southern California Compositions thérapeutiques comprenant des monoterpènes
CN102470130B (zh) 2009-07-15 2013-09-04 施万制药 联苯化合物的结晶游离碱形式
BR112012022209A2 (pt) 2010-03-03 2017-06-06 Neonc Tech Inc composições farmacêuticas compreendendo monoterpenos
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
BR112013004698B1 (pt) 2010-08-27 2022-03-22 Neonc Technologies Inc. Composições farmacêuticas compreendendo derivados de poh
DK2651864T3 (en) 2010-12-17 2016-09-05 Neonc Tech Inc Methods and devices for use of isoperillylalkohol
PL2968312T3 (pl) 2013-03-15 2018-08-31 Verona Pharma Plc Kombinacja leków
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
HUE048020T2 (hu) 2014-05-12 2020-05-28 Verona Pharma Plc Új kezelés
CN112142749A (zh) 2015-02-12 2020-12-29 NeOnc技术股份有限公司 紫苏醇衍生物、药物组合物及其用途
US10858305B2 (en) 2016-11-30 2020-12-08 Neonc Technologies, Inc. Perillyl alcohol-3-bromopyruvate conjugate and methods of treating cancer
CA3225993A1 (fr) 2018-02-08 2019-08-15 University Of Southern California Utilisation du monoterpene, du sesquiterpene ou de leurs derives pour permeabiliser la barriere hemato-encephalique

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SE9101090D0 (sv) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
US5639441A (en) 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
AU695207B2 (en) 1995-03-28 1998-08-06 Fidia Farmaceutici S.P.A. Nanospheres comprising a biocompatible polysaccharide
CN1149076C (zh) 1997-03-20 2004-05-12 先灵公司 粉末附聚物的制备方法

Also Published As

Publication number Publication date
IL143040A0 (en) 2002-04-21
US6475524B1 (en) 2002-11-05
PL348523A1 (en) 2002-06-03
IS5946A (is) 2001-05-18
DE69930158D1 (de) 2006-04-27
AU2010400A (en) 2000-06-13
WO2000030614A1 (fr) 2000-06-02
ATE318583T1 (de) 2006-03-15
SE9804000D0 (sv) 1998-11-23
EP1133285B1 (fr) 2006-03-01
NZ511494A (en) 2003-11-28
ES2258865T3 (es) 2006-09-01
EE200100275A (et) 2002-10-15
JP2002530319A (ja) 2002-09-17
CA2349633A1 (fr) 2000-06-02
CN1198592C (zh) 2005-04-27
DE69930158T2 (de) 2006-11-16
AU767313B2 (en) 2003-11-06
TR200101424T2 (tr) 2001-12-21
SK7032001A3 (en) 2001-11-06
KR20010080534A (ko) 2001-08-22
CN1328447A (zh) 2001-12-26
CZ20011778A3 (cs) 2001-08-15
EP1133285A1 (fr) 2001-09-19
NO20012514L (no) 2001-07-19
BR9915592A (pt) 2001-08-07
PT1133285E (pt) 2006-06-30
IL143040A (en) 2009-09-01
CA2349633C (fr) 2009-06-02
NO20012514D0 (no) 2001-05-22
DK1133285T3 (da) 2006-06-06
KR100697780B1 (ko) 2007-03-21
HUP0104182A2 (hu) 2002-03-28
JP4447169B2 (ja) 2010-04-07
CY1105609T1 (el) 2010-07-28

Similar Documents

Publication Publication Date Title
IL143040A (en) Process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state
CA2348084A1 (fr) Methode de cristallisation utilisant des fluides supercritiques ou des fluides sous-critiques
NZ514574A (en) Novel method of treatment
WO2001009118A3 (fr) Composes dithiolthione pour le traitement de troubles neurologiques et pour renforcer la memoire
CA2149242A1 (fr) Derive de la quinuclidine pour le traitement de troubles inflammatoires et gastro-intestinaux
WO2001041761A3 (fr) Compositions de valdecoxib
CA2366268A1 (fr) Compositions pharmaceutiques pour le traitement de maladies du snc et d'autres maladies
WO1996015786A3 (fr) Compositions orales contenant de l'ondansetron
BG104476A (en) Therapeutical form for tolterodin with controlled release
WO2003024387A3 (fr) Methode et composition pharmaceutique destinees au traitement d'inflammations
HUT60630A (en) Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature
HUP0202461A2 (hu) Gyógyászati készítmények és azok agyvérzés, diabetes és/vagy elzáródásos szívbénulás megelőzésében történő alkalmazása
CA2306393A1 (fr) Utilisation d'acide 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz£b,e]oxepine-2-acetique dans la production d'un medicament de traitement de troubles ophtalmiques inflammatoires non allergiques et de prevention de la neoformation de vaisseaux sanguins oculaires
CA2330480A1 (fr) Preparation a liberation controlee de divalproex sodium
CA2198706A1 (fr) Procedes de traitement de l'arthrite
NO962752L (no) Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose
CA2501738A1 (fr) Procede de traitement du syndrome de douleur pelvienne chronique par administration de gonadotropine chorionique
ZA906057B (en) 4-(n-substituted amino)-2-butynyl-1-ureas and thioureas and derivatives thereof as centrally acting muscarinic agents
WO2001042272A3 (fr) Forme cristalline d'eplerenone possedant une vitesse de dissolution accrue
UA74388C2 (uk) Фармацевтичні композиції тизоксаніду і нітазоксаніду
CA2279943A1 (fr) Traitement des affections de la peau
EP0743068A3 (fr) Composition pour inhiber la perte osseuse contentant du sulfate de vanadium
WO2002076437A3 (fr) Methodes de traitement de maladies neurodegeneratives, y compris de la maladie d'alzheimer
WO1999021005A3 (fr) Millepertuis de qualite pharmaceutique
WO2003042136A3 (fr) Procede de production d'ester ethylique de l-dopa